HUN Q3 Earnings Miss Estimates, Sales Beat on Higher Prices

Huntsman’s Q3 2026 adjusted EPS of $0.04 missed the $0.07 consensus by 42.9%, while revenue rose 17.6% year over year to $1.72 billion, 7.2% above estimates, and adjusted EBITDA increased 40.4% to $132 million. Free cash flow fell to $82 million from $157 million a year earlier, and net debt excluding affiliates was $1.684 billion. Management expects net-debt leverage to reach about 4x by year-end; the planned merger with Olin is expected to close in Q1 2027, subject to remaining regulatory approvals.

Analysis

The key distinction is between price-led recovery and demand-led recovery. Polyurethanes’ sharp EBITDA improvement on modest volume growth leaves earnings exposed if MDI pricing weakens or raw-material costs rise faster than selling prices; Performance Products’ flat-to-down volumes similarly suggest limited underlying demand leverage. Advanced Materials’ volume growth is the more constructive signal, but its durability depends on end-market activity rather than mix and pricing.

The main second-order risk is cash conversion: EBITDA improved while operating cash flow and free cash flow fell, and net debt increased. If working capital absorbs the recovery, the promised deleveraging becomes harder to deliver and reduces flexibility ahead of the planned combination with Olin Corporation (OLN). For OLN, the transaction is an event and integration-risk exposure, not yet a clearly quantifiable earnings catalyst: consideration, pro forma leverage, and synergy details are not provided here.

Over the next 1–3 months, watch MDI pricing versus feedstock costs, segment volumes, and cash conversion. Over 6–18 months, remaining regulatory approvals and transaction terms determine whether the combination creates value or adds execution and balance-sheet risk. The contrarian point: headline sales growth can overstate recovery when pricing does most of the work; a sustained improvement in volumes and free cash flow would be more probative.

Key Decisions for Investors

• Avoid treating the quarter as confirmation of a durable earnings turn; keep Huntsman exposure neutral until volume growth and cash conversion validate the recovery.
• Use the next report as a catalyst check: reassess if MDI price-cost spreads reverse, Advanced Materials volumes contract, or operating cash flow remains weak despite higher EBITDA.
• For OLN, keep the merger on an event-risk watchlist rather than initiating a merger-arbitrage position: verify consideration/exchange terms, pro forma leverage, expected synergies, and remaining regulatory conditions first.
• A more constructive stance requires net debt to begin declining alongside earnings and management’s leverage trajectory to remain credible; deterioration in cash conversion or a delay to the expected close would falsify that case.